Pioglitazone Did Not Delay Cognitive Impairment in People at Risk of Alzheimer Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Pioglitazone for the Delay of Cognitive Impairment in People at Risk of Alzheimer's Disease (TOMMORROW): A Prognostic Biomarker Study and a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet Neurol 2021 Jul 01;20(7)537-547, DK Burns, RC Alexander, KA Welsh-Bohmer, M Culp, C Chiang, J O'Neil, RM Evans, P Harrigan, BL Plassman, JR Burke, J Wu, MW Lutz, S Haneline, AJ Schwarz, LS Schneider, K Yaffe, AM Saunders, E RattiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.